AZD2811 + azacitidine

This is a **combination drug** consisting of AZD2811 and azacitidine. - **AZD2811** is a potent, selective small-molecule inhibitor of Aurora kinase B, a key regulator of mitosis. AZD2811 is formulated as a nanoparticle for intravenous administration and is being developed primarily for the treatment of hematological malignancies, especially acute myeloid leukemia (AML). - **Azacitidine** is a nucleoside metabolic inhibitor and DNA methyltransferase inhibitor that incorporates into DNA and RNA, resulting in hypomethylation and disruption of abnormal gene expression. - The combination is under clinical investigation for synergistic antileukemic effects that stem from concomitant inhibition of cell-cycle progression (via Aurora kinase B inhibition by AZD2811) and epigenetic modulation (via DNA methyltransferase inhibition by azacitidine). - Preclinical studies have shown enhanced efficacy of the combination compared to either agent alone in AML models. - Developed for patients not eligible for intensive induction therapy, the combination is being trialed in relapsed/refractory or newly diagnosed AML.

Other names

AZD2811 nanoparticle + azacitidineAZD2811/azacitidine